4 results about "HCG - Human chorionic gonadotropin" patented technology

A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.

This provides a means to continuously, concisely, and objectively visualize the trends in measurement results. [Solution] An in vitro diagnostic test kit for determining information on human chorionic gonadotropin contained in the urine of a subject in multiple stages, comprising one or more detectors equipped with a capture member that specifically binds to human chorionic gonadotropin upon contact with a sample, wherein one or more visual indicator parts provided on the detector itself exhibit multiple visual states that can be identified by at least one of position, hue, intensity, or number of appearances upon reaction with urine, and the visual states or combinations thereof are associated with multiple judgment criteria corresponding to human chorionic gonadotropin.

The present application adopts human chorionic gonadotropin and indocyanine green-succinimidyl ester to carry out coupling reaction, and provides an ovarian follicle near-infrared fluorescent probe, and the preparation method of the probe is as follows: indocyanine green-succinimidyl ester solution and human chorionic gonadotropin solution are added into phosphate buffer solution with pH of 7.4-7.5 according to a proper ratio to obtain a mixed solution, stirring is carried out to react, and then the product is purified. The ovarian follicle near-infrared fluorescent probe provided by the present application has the advantages of rich raw material source, low cost, high clinical transformation and application value compared with the prior art, and has the characteristics of strong specificity, good light stability, deep penetration, high spatial resolution, fast biological metabolic rate, stable observation time window, no toxic side effects, and the like. The preparation method of the probe is simple in operation, good in stability and repeatability. The present application further provides an ovarian follicle contrast agent containing the ovarian follicle near-infrared fluorescent probe, and the contrast agent has high targeting, strong contrast, no toxic side effects and fast biological metabolic rate.

The invention provides optimized upstream processes for the production of recombinant gonadotropins including corifollitropin alfa (CFA), recombinant human chorionic gonadotropin (r-hCG), and recombinant human follicle- stimulating hormone (r-hFSH) in mammalian cell culture. The processes comprise revival of CHO cells from cryopreservation, expansion in shake flasks, seed generation in wave bioreactors, and production in stirred-tank bioreactors operated in fed-batch mode. Defined media supplemented with additives such as N-acetyl mannosamine, or stabilized glutamine enhance cell viability, productivity, and glycosylation quality. Cultures are terminated at defined viability thresholds or timepoints, and clarified by sequential depth and membrane filtration. The methods offer scalability, reproducibility, and superior product quality compared to conventional approaches, enabling consistent large-scale manufacture of therapeutic gonadotropins for fertility treatments and hormone therapies.